The effect of pristane on ascites tumor formation and monoclonal antibody production.
Preinjection of mice 10 days before intraperitoneal injections of hybridomas gives optimum development of ascites tumors with respect to the rate at which tumors form, percentage of mice developing tumors, volume of ascites fluid produced, and concentration of monoclonal antibody in ascites fluid. The dose of pristane injected has little or no effect on ascites formation down to 0.1 ml of pristane.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000032:analysis / Q000096:biosynthesis*; D002273:Carcinogens / Q000494:pharmacology*; D006825:Hybridomas / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D007074:Immunoglobulin G / Q000032:analysis / Q000096:biosynthesis*; D007075:Immunoglobulin M / Q000032:analysis / Q000096:biosynthesis*; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000473:pathology*; D013729:Terpenes / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D002273:Carcinogens; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D013729:Terpenes; C009042:pristane